CHRM1 and neuropathy: For example, studies in preclinical models of HIV-associated neuropathy have shown that M1R antagonists prevent impaired neurite outgrowth In vitro, prevent and reverse loss of corneal nerves when applied topically to the eye, and prevent NCV slowing, paw heat hypoalgesia, and loss of corneal nerves following systemic delivery [41,50].